Abstract: Isavuconazole is a novel triazole antifungal agent that has not yet been marketed in China. It has a broad antifungal spectrum. In vitro studies and clinical trials have shown that it's active against molds, yeasts, dimorphic fungi and some rare fungi, that it is effective for clinical treatment of infection at special sites such as the central nervous system, and that the blood concentration of isavuconazole is stable, with good safety and tolerability, and with fewer adverse events during long-term use. This review summarizes the pharmacological characteristics and clinical research progress of isavuconazole, aiming to provide reference for clinical medication.